Anidulafungin + Voriconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia, Invasive Candidiasis
Trial Timeline
Feb 1, 2008 → Oct 1, 2009
NCT ID
NCT00548262About Anidulafungin + Voriconazole
Anidulafungin + Voriconazole is a approved stage product being developed by Pfizer for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00548262. Target conditions include Candidemia, Invasive Candidiasis.
What happened to similar drugs?
3 of 7 similar drugs in Candidemia were approved
Approved (3) Terminated (2) Active (3)
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00548262 | Approved | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 43 |
| Micafungin | Astellas Pharma | Approved | 35 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 32 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Anidulafungin | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |